Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Abstract Currently, 33 gene‐therapy drugs/products have been approved in the clinic. Over
3000 completed and ongoing clinical gene therapy trials have been reported worldwide …

Leishmaniasis is endemic to the tropical and subtropical regions of the world and is
transmitted by the bite of an infected sand fly. The multifaceted interactions between …

Migration of leukocytes to the site of microbial infection is important for the development of
effective host immunity. Recombinant modified vaccinia virus Ankara is frequently used as a …

Zaire and Sudan ebolavirus species cause a severe disease in humans and nonhuman
primates (NHPs) characterized by a high mortality rate. There are no licensed therapies or …

Immune-to-brain communication pathways involve humoral mediators, including cytokines,
central modulation by neuronal afferents and immune cell trafficking to the brain. During …

Evidence suggests that neutrophils exert specialized effector functions during infection and
inflammation, and that these cells can affect the duration, severity, and outcome of the …

Poxviruses use a complex strategy to escape immune control, by expressing
immunomodulatory proteins that could limit their use as vaccine vectors. To test the role of …

Oncolytic viruses (OVs), above and beyond infecting and lysing malignant cells, interact with
the immune system in complex ways that have important therapeutic significance. While …

No licensed vaccine exists against visceral leishmaniasis (VL), a disease caused by the
Leishmania donovani parasite. We have previously reported both macrophages and …